EUVIMEDEUVIMED entdecken
Crossref

Real-World Treatment Pathways in Stage III Non-Small-Cell Lung Cancer Surgical Patients in Portugal

Encarnação Teixeira, Gabriela Fernandes, Lurdes Ferreira, F. Estevinho, J.A. Lopes, António Araújo, Maria Manuel Figueiredo, Lourdes Barradas, Miguel Lopes, Ulisses Brito, C. Camacho, Bárbara Parente und 7 weitere

Revista do Grupo de Estudos do Cancro do Pulmão · 23.03.2026

DOI: 10.82582/thorac.92 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Revista do Grupo de Estudos do Cancro do Pulmão, erschienen am 23.03.2026. Verfasst von Encarnação Teixeira und 18 weiteren Autor:innen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Stage III non-small-cell lung cancer (NSCLC) is a complex and heterogeneous disease, with no established optimal treatment sequence. We aimed to characterize surgically treated patients with stage III NSCLC in Portugal.

Methods

PICTuRE was a multicentric, retrospective study. Adults with stage III NSCLC diagnosed in 2018 were followed until disease progression, death, loss of follow-up, or end of study. Overall survival and disease-free survival were estimated using the Kaplan-Meier method.

Results

Of 278 patients included in PICTuRE, 59 (21.2%) underwent surgery. Surgical patients had a mean age of 65±9 years and were predominantly men (57.6%) and current/former smokers (79.3%). Most presented with adenocarcinoma (71.2%) and stage IIIA disease (79.7%), with ECOG 0-1. All patients underwent at least one non-invasive staging method, while 64.4% received minimally invasive/invasive staging. Lag-times from multidisciplinary team decision to surgery ranged from approximately 1 to 11 months. Neoadjuvant treatment was administered to 22 patients. Resection margins were available for 50 patients (84% R0; 16% R1/R2). Operative mortality and morbidity rates were 3.4% and 25.5%, respectively. Adjuvant treatment was administered to 87.7% of patients, primarily chemoradiotherapy (50%). Median disease-free survival was 22 months, while overall survival was not reached.

Conclusion

The real-world analysis of the surgical population in the Portuguese PICTuRE study highlights the complexity and heterogeneity of stage III NSCLC, as well as the ongoing challenges in disease management. Although some recommendations and algorithms for tumour staging exist, practices are not yet consensual, particularly for N2 patients, with few undergoing minimally invasive or invasive methods. No single optimal treatment strategy exists due to variability in tumour extension and nodal involvement; nonetheless, multimodality treatment, including neoadjuvant therapy followed by surgery and adjuvant therapy, may potentially improve survival outcomes. Optimal therapeutic strategy requires careful balancing of patient characteristics, treatment effectiveness and safety within an MDT in a timely process (i.e., reduced delays between diagnosis, staging and treatment initiation). This approach may ensure the delivery of tailored approaches and optimize outcomes for this population. Further studies should evaluate the impact of novel therapies, such as immunotherapy, on treatment patterns and patient outcomes in real-world settings.

Schlagwörter

stage III NSCLCsurgical treatmentneoadjuvant therapyadjuvant chemoradiotherapytreatment pathwayslymph node stagingsurgical marginsoverall survivaldisease-free survivalmultidisciplinary team

Zitieren

APA

Teixeira, E., Fernandes, G., Ferreira, L., Estevinho, F., Lopes, J., Araújo, A., Figueiredo, M. M., Barradas, L., Lopes, M., Brito, U., Camacho, C., Parente, B., Felizardo, M., Meleiro, A., Bernardo, M., Antunes, C. M., Bernardo, F., Figueiredo, & Sara (2026). Real-World Treatment Pathways in Stage III Non-Small-Cell Lung Cancer Surgical Patients in Portugal. Revista do Grupo de Estudos do Cancro do Pulmão. https://doi.org/10.82582/thorac.92

Vancouver

Teixeira E, Fernandes G, Ferreira L, Estevinho F, Lopes J, Araújo A, et al. Real-World Treatment Pathways in Stage III Non-Small-Cell Lung Cancer Surgical Patients in Portugal. Revista do Grupo de Estudos do Cancro do Pulmão. 2026. doi:10.82582/thorac.92

BibTeX
@article{Teixeira2026,
  author = {Teixeira, Encarnação and Fernandes, Gabriela and Ferreira, Lurdes and Estevinho, F. and Lopes, J.A. and Araújo, António and Figueiredo, Maria Manuel and Barradas, Lourdes and Lopes, Miguel and Brito, Ulisses and Camacho, C. and Parente, Bárbara and Felizardo, Margarida and Meleiro, António and Bernardo, Manuela and Antunes, Carolina Monteiro and Bernardo, Filipa and Figueiredo and Sara},
  title = {Real-World Treatment Pathways in Stage III Non-Small-Cell Lung Cancer Surgical Patients in Portugal},
  journal = {Revista do Grupo de Estudos do Cancro do Pulmão},
  year = {2026},
  doi = {10.82582/thorac.92}
}
Kostenlos starten →